8-KItem 5.02 · Officer/Director ChangeItem 7.01 · Reg FD DisclosureItem 9.01 · Financial Statements

Quest Diagnostics ($DGX) filed a Form 8‑K on Mar 12, 2026 — Item 9.01 lists exhibits: Press release dated…

Filed with the SEC on March 12, 2026 · Summarized by InvestorsBot

Quest Diagnostics ($DGX) filed a Form 8‑K on Mar 12, 2026 — Item 9.01 lists exhibits: Press release dated Mar 12, 2026 (Ex.99.1) and Inline XBRL cover page (Ex.104). No financial statements attached. Signed by Sean D. Mersten. 🧾📅 #SECfiling #QuestDiagnostics

Investor note: The 8‑K attaches a March 12 press release — review that release for any operational or strategic updates; this filing itself contains exhibits only, not new financial disclosures. $DGX 🔎🩺 #8K #Healthcare

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from QUEST DIAGNOSTICS INC

Quest Diagnostics Reports Q2 Growth and Raises 2026 Guidance

8-K · July 23, 2026

Quest Diagnostics ($DGX) disclosed (Reg FD) that Mr.

8-K · March 12, 2026

On Mar 9, 2026 Quest Diagnostics ($DGX) added Timothy Wentworth, former CEO of Walgreens Boots Alliance,…

8-K · March 12, 2026

Quest Diagnostics ($DGX) filed a Form 8-K on Feb 10, 2026 attaching a press release with Q4 & FY 2025…

8-K · February 10, 2026

Quest Diagnostics ($DGX) Board of Directors authorized an additional $1.0B of common stock repurchases…

8-K · February 10, 2026

Quest Diagnostics ($DGX) filed an 8‑K (Item 2.02) on Feb 10, 2026 announcing Q4 and full‑year results for…

8-K · February 10, 2026